Afamelanotide vs Somapacitan: Key Differences & Uses

Afamelanotide and Somapacitan are both FDA-approved peptides, but they work in entirely different ways and treat different conditions. Afamelanotide is a melanocortin receptor agonist designed to stimulate melanin production and protect skin from UV damage, approved for erythropoietic protoporphyria (EPP). Somapacitan is a long-acting growth hormone analog for growth hormone deficiency. While both are approved by major regulatory bodies and backed by solid clinical evidence, they address separate medical needs. Understanding which is which—and why they're not interchangeable—matters if you're researching peptide therapies.

What Is Afamelanotide?

Afamelanotide is a synthetic peptide that mimics α-melanocyte-stimulating hormone (α-MSH), a naturally occurring signaling molecule in your body. It works by binding to melanocortin-1 receptors (MC1R) on melanocytes—the cells that produce melanin, the pigment that colors your skin.

The FDA approved afamelanotide in 2023 under the brand name Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder where patients suffer severe phototoxic reactions—painful blistering and burning—when exposed to sunlight. By boosting melanin production, afamelanotide increases natural photoprotection, allowing patients to tolerate more sun exposure safely.

Clinical evidence from 23 trials shows afamelanotide reduces phototoxic reactions in EPP patients by an average of 25–50%, with some patients experiencing much greater relief. The EMA approved the compound in 2014, making it available across Europe as well. Notably, Health Canada has not approved afamelanotide.

Afamelanotide is administered as a subcutaneous implant (a small rod inserted under the skin) that releases the peptide gradually over months, offering sustained action without frequent dosing.

What Is Somapacitan?

Somapacitan is a long-acting recombinant human growth hormone (rhGH) analog. Unlike natural growth hormone, which is released in pulses and has a short half-life (15–20 minutes), somapacitan is conjugated with a polyethylene glycol (PEG) polymer that extends its duration in the bloodstream to roughly 5–6 days per dose.

The FDA approved somapacitan in 2021 under the brand name Somavarni for growth hormone deficiency (GHD) in both children and adults. The EMA and Health Canada have also approved it, giving somapacitan the broadest regulatory reach of the two compounds.

Growth hormone deficiency is a metabolic disorder where insufficient hormone production leads to reduced muscle mass, increased fat deposition, low bone density, fatigue, and metabolic dysfunction. Somapacitan replaces the missing hormone, restoring normal growth and metabolic function.

21 clinical trials have demonstrated that somapacitan improves lean body mass, reduces fat mass, enhances quality of life, and stabilizes bone mineral density in GHD patients. Because it's dosed once weekly (or sometimes less frequently), it offers better adherence than traditional daily growth hormone injections.

Clinical Evidence: Head-to-Head Comparison

Both compounds have strong clinical backing (Evidence Grade A), but the evidence supports different outcomes:

Afamelanotide: Phase III trials showed that afamelanotide reduced phototoxic events by 25–50% in EPP patients compared to placebo. Safety data from 23 trials confirms melanin-stimulating peptides are well-tolerated when used as directed, though some patients report mild darkening of existing moles and rare cases of nausea. The mechanism is straightforward: more melanin = more UV absorption = fewer photosensitive reactions.

Somapacitan: Clinical trials in adult GHD patients showed somapacitan restored lean body mass, improved lipid profiles, and enhanced quality-of-life scores to levels comparable or superior to daily growth hormone therapy. In children, somapacitan achieved near-normal growth velocity. The once-weekly dosing significantly improves compliance compared to daily injections, which historically has been a major barrier to consistent treatment.

Neither compound competes on the same clinical stage—they treat fundamentally different disorders.

Regulatory Status & Availability

| Aspect | Afamelanotide | Somapacitan | |--------|---------------|--------------| | US FDA | Approved (2023) | Approved (2021) | | EMA | Authorised (2014) | Authorised (2021) | | Health Canada | Not approved | Approved | | Clinical Trials | 23 | 21 | | Primary Indication | Erythropoietic protoporphyria | Growth hormone deficiency |

Somapacitan has the edge in terms of global availability. Afamelanotide, approved more recently by the FDA but earlier in Europe, remains unavailable in Canada.

Key Mechanistic Differences

Target Pathway:

Afamelanotide activates melanocortin receptors to stimulate endogenous melanin synthesis. It's working with your body's natural pigmentation machinery.
Somapacitan is a direct hormonal replacement. It's synthetic growth hormone in your bloodstream, replacing what your body doesn't make.

Duration & Dosing:

Afamelanotide is a subcutaneous implant lasting several months per insertion.
Somapacitan is injected once weekly (or less frequently in some protocols).

Onset:

Afamelanotide takes 2–4 weeks to significantly increase skin melanin; photoprotection builds gradually.
Somapacitan begins working within days; metabolic changes accumulate over weeks to months.

Side Effect Profiles: Both are generally well-tolerated. Afamelanotide can darken existing moles or cause mild nausea; somapacitan may cause transient joint pain, edema, or carpal tunnel-like symptoms, particularly in adults with severe GHD who are being repleted.

Who Should Consider Each Compound?

Afamelanotide Is Best For:

Patients with erythropoietic protoporphyria who suffer debilitating photosensitive reactions and want to expand their outdoor activities and quality of life.
Those seeking a long-lasting implant option rather than frequent injections or daily medications.
Individuals approved by their physician in the US, EU, or other markets where it's licensed.

Afamelanotide is not indicated for cosmetic skin darkening, despite historical misuse in grey-market contexts. It is strictly a therapeutic tool for a rare genetic disease.

Somapacitan Is Best For:

Adults and children diagnosed with growth hormone deficiency (via provocative testing) who need long-term hormone replacement.
Patients struggling with daily injection compliance—the once-weekly schedule is a major practical advantage over older GH formulations.
Those seeking a metabolically restorative therapy with documented improvements in body composition, bone health, and cardiovascular risk factors.
Individuals in any of the three major markets (US, EU, or Canada), given its broad regulatory approval.

The Bottom Line

Afamelanotide and Somapacitan are both premium, FDA-approved peptides with robust clinical evidence—but they solve completely different problems. Afamelanotide is a niche therapy for a rare phototoxic disorder; Somapacitan is a mainstream replacement hormone for a more common metabolic deficiency.

If you're researching peptide therapies, asking "which is better?" is like asking whether a blood pressure medication or an antibiotic is better. The answer depends entirely on what condition you're treating. The key is working with a licensed physician who can diagnose the underlying condition and prescribe the appropriate peptide—or neither, depending on your health profile.

For more context on how peptides work in general, see our guides to peptide mechanisms and receptor agonists. You might also compare these to related compounds like Tesamorelin (another growth hormone–releasing peptide) or Melanotan II (a melanocortin agonist in research).

FAQ

Q: Can afamelanotide and somapacitan be used together? A: They target entirely different systems (melanin vs. growth hormone) and are approved for different indications. Combined use would be off-label and should only be considered by a physician managing multiple diagnoses. There are no studies on combination therapy.

Q: Is afamelanotide safe for long-term use? A: Clinical data from 23 trials spanning several years shows afamelanotide is well-tolerated with a favorable safety profile. Mild darkening of moles and occasional nausea are the most common side effects. Annual skin checks are recommended for EPP patients on long-term therapy.

Q: How much more convenient is somapacitan than daily growth hormone? A: Somapacitan is dosed once weekly versus daily injections (sometimes twice daily) with older formulations. This 7-fold reduction in injection frequency significantly improves adherence and quality of life for GHD patients.

Q: Why is afamelanotide approved in Europe but not yet in Canada? A: Regulatory approvals vary by region. The EMA approved afamelanotide in 2014 after demonstrating safety in EPP populations; Health Canada has not yet approved it (as of 2024). Somapacitan achieved approval in all three major markets more recently.

Q: Are these peptides available without a prescription? A: No. Both are prescription-only compounds in all approved markets. They require a physician diagnosis, monitoring, and ongoing clinical oversight.

Afamelanotide vs Somapacitan: What's the Difference?